Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier

Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders

Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969

Blood–brain barrier delivery

Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168

Astroglial networks: a step further in neuroglial and gliovascular interactions

Giaume, C., Koulakoff, A., Roux, L., Holcman, D., & Rouach, N. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2757 · Cited by 789

Cord-Blood Transplants from Unrelated Donors in Patients with Hurler's Syndrome

Staba, S. L., Escolar, M. L., Poe, M. D., Kim, Y., Martin, P., Szabolcs, P., Allison-Thacker, J., Wood, S. J., Wenger, D. A., Rubinstein, P., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032613 · Cited by 475

Drug and gene targeting to the brain with molecular trojan horses

Pardridge, W. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd725 · Cited by 439

Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B,E receptors.

Hui, D. Y., Innerarity, T. L., & Mahley, R. W. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69254-9 · Cited by 383

Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome

Peters, C., Balthazor, M., Shapiro, E., King, R., Kollman, C., Hegland, J., Henslee-Downey, J. P., Trigg, M. E., Cowan, M. J., Sanders, J. E., et al. (1996) · Blood · doi:10.1182/blood.v87.11.4894.bloodjournal87114894 · Cited by 315

Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain

Kreuter, J., Hekmatara, T., Dreis, S., Vogel, T., Gelperina, S. E., & Langer, K. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.12.012 · Cited by 263

Targeted delivery of proteins across the blood–brain barrier

Spencer, B. J., & Verma, I. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702170104 · Cited by 249

Strategies for delivering therapeutics across the blood–brain barrier

Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622

Nanobodies as therapeutics: big opportunities for small antibodies

Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 476

Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery

Oller‐Salvia, B., Sánchez‐Navarro, M., Giralt, E., & Teixidò, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 463

Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier

Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399

Brain-targeted drug delivery by manipulating protein corona functions

Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

Bors, L. A., & Erdő, F. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87010006 · Cited by 263

Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis

Huang, J., Jiang, G., Song, Q., Gu, X. Q., Meng, H., Wang, X.-L., Song, H., Chen, L., Lin, Y., Jiang, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15144 · Cited by 212

Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma

Jiang, Y., Zhang, J., Meng, F., & Zhong, Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b05265 · Cited by 201

Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System

Pattipeiluhu, R., Arias‐Alpizar, G., Basha, G., Chan, K. Y. T., Bussmann, J., Sharp, T. H., Moradi, M., Sommerdijk, N., Harris, E. N., Cullis, P. R., et al. (2022) · Advanced Materials · doi:10.1002/adma.202201095 · Cited by 194

Nanostructures: a platform for brain repair and augmentation

Vidu, R., Rahman, M., Mahmoudi, M., Enăchescu, M., Potecă, T. D., & Opriș, I. C. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00091 · Cited by 140

Receptor Ligand-Free Mesoporous Silica Nanoparticles: A Streamlined Strategy for Targeted Drug Delivery across the Blood–Brain Barrier

Chen, Z.-A., Wu, C. ‐., Wu, S., Huang, C.-Y., Mou, C., Wei, K., Yen, Y., Chien, I.-T., Runa, S., Chen, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c08993 · Cited by 132

Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology

Moura, R. P., Martins, C., Pinto, S. F. T., Sousa, F., & Sarmento, B. F. C. C. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1583205 · Cited by 127

Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I

Gomez‐Ospina, N., Scharenberg, S. G., Mostrel, N., Bak, R. O., Mantri, S., Quadros, R. M., Gurumurthy, C. B., Lee, C. M., Bao, G., Suarez, C. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11962-8 · Cited by 124

LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases

Guo, Q., Zhu, Q., Miao, T., Tao, J., Ju, X., Sun, Z., Li, H., Xu, G., Chen, H., & Han, L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.031 · Cited by 119

Cell-Penetrating and Targeted Peptides Delivery Systems as Potential Pharmaceutical Carriers for Enhanced Delivery across the Blood–Brain Barrier (BBB)

Ghorai, S. M., Deep, A., Magoo, D., Gupta, C., & Gupta, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071999 · Cited by 124

Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy

He, W., Li, X., Morsch, M., Ismail, M., Liu, Y., Rehman, F. U., Zhang, D., Wang, Y., Zheng, M., Chung, R. S., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c00320 · Cited by 116

Use of LDL receptor—targeting peptide vectors for in vitro and in vivo cargo transport across the blood‐brain barrier

Molino, Y., David, M., Varini, K., Jabès, F., Gaudin, N., Fortoul, A., Bakloul, K., Masse, M., Bernard, A., Drobecq, L., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201600827r · Cited by 118

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions

Nhàn, N. T. T., Yamada, T., & Yamada, K. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612931 · Cited by 114

Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A

Böckenhoff, A., Cramer, S., Wölte, P., Knieling, S., Wohlenberg, C., Gieselmann, V., Galla, H., & Matzner, U. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4785-13.2014 · Cited by 103

Transportation of Single-Domain Antibodies through the Blood–Brain Barrier

Ruiz-López, E., & Schuhmacher, A. J. (2021) · Biomolecules · doi:10.3390/biom11081131 · Cited by 104

Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders

Salvalaio, M., Rigon, L., Belletti, D., D’Avanzo, F., Pederzoli, F., Ruozi, B., Marin, O., Vandelli, M. A., Forni, F., Scarpa, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156452 · Cited by 93

Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement

Hampe, C. S., Wesley, J. B., Lund, T. C., Orchard, P. J., Polgreen, L. E., Eisengart, J. B., McLoon, L. K., Cüreoğlu, S., Schachern, P. A., & McIvor, R. S. (2021) · Biomolecules · doi:10.3390/biom11020189 · Cited by 94

Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges

Parrasia, S., Szabó, I., Zoratti, M., & Biasutto, L. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00523 · Cited by 95

Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms

Gleitz, H. F. E., Liao, A. Y., Cook, J. R., Rowlston, S., Forte, G. M. A., D’Souza, Z., O’Leary, C., Holley, R. J., & Bigger, B. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708730 · Cited by 85

Biomimetic drug-delivery systems for the management of brain diseases

Chen, Y., Wei, C., Lyu, Y., Chen, H., Jiang, G., & Gao, X. (2019) · Biomaterials Science · doi:10.1039/c9bm01395d · Cited by 89

Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis

Geraets, R. D., Koh, S. Y., Hastings, M. L., Kielian, T., Pearce, D. A., & Weimer, J. M. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0414-2 · Cited by 87

Concepts, technologies, and practices for drug delivery past the blood–brain barrier to the central nervous system

Crawford, L., Rosch, J. G., & Putnam, D. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.041 · Cited by 84

Therapeutic potential of polypeptide-based conjugates: Rational design and analytical tools that can boost clinical translation

Melnyk, T., Đorđević, S., Conejos‐Sánchez, I., & Vicent, M. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.007 · Cited by 81

The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin

Zhang, Y., Li, Y., Hu, Q., Xi, Y. T., Xing, Z., Zhang, Z., Huang, L. A., Wu, J., Liang, K., Nguyen, T. K., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-00595-5 · Cited by 80

Treatment of brain disease in the mucopolysaccharidoses

Scarpa, M., Orchard, P. J., Schulz, A., Dickson, P., Haskins, M. E., Escolar, M. L., & Giugliani, R. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.10.007 · Cited by 72

CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges

Edelmann, M. J., & Maegawa, G. H. B. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.559804 · Cited by 65

1988–2018: Thirty years of drug smuggling at the nano scale. Challenges and opportunities of cell-penetrating peptides in biomedical research

Gallo, M., Defaus, S., & Andreu, D. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.010 · Cited by 66

The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells

Tian, W., Ye, Z., Wang, S., Schulz, M. A., Coillie, J. V., Sun, L., Chen, Y., Narimatsu, Y., Hansen, L. H., Kristensen, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09809-3 · Cited by 63

Lysosomal storage disease: Gene therapy on both sides of the blood–brain barrier

Aronovich, E. L., & Hackett, P. B. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.011 · Cited by 63

Delivery of Nanoparticles and Macromolecules across the Blood–Brain Barrier

Nowak, M., Helgeson, M. E., & Mitragotri, S. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900073 · Cited by 60

Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood–brain barrier transport

Díaz‐Perlas, C., Oller‐Salvia, B., Sánchez‐Navarro, M., Teixidò, M., & Giralt, E. (2018) · Chemical Science · doi:10.1039/c8sc02415d · Cited by 59

Dual‐Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy

Zhang, Y., Ma, H., Li, L.-S., Sun, C., Yu, C., Wang, L., Xu, D., Song, X., & Yu, R. (2024) · Advanced Materials · doi:10.1002/adma.202400502 · Cited by 57

Blood–brain barrier peptide shuttles

Sánchez‐Navarro, M., Giralt, E., & Teixidò, M. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.04.019 · Cited by 57

A highly efficacious PS gene editing system corrects metabolic and neurological complications of mucopolysaccharidosis type I

Ou, L., Przybilla, M. J., Ahlat, O., Kim, S., Overn, P., Jarnes, J., O’Sullivan, M. G., & Whitley, C. B. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.018 · Cited by 56

Peptide Shuttles for Blood–Brain Barrier Drug Delivery

Sánchez‐Navarro, M., & Giralt, E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091874 · Cited by 58

Setting-up an In Vitro Model of Rat Blood-brain Barrier (BBB): A Focus on BBB Impermeability and Receptor-mediated Transport

Molino, Y., Jabès, F., Lacassagne, E., Gaudin, N., & Khrestchatisky, M. (2014) · Journal of Visualized Experiments · doi:10.3791/51278 · Cited by 69

Targeting with nanoparticles for the therapeutic treatment of brain diseases

Jin, G., Chakraborty, A., Lee, J., Knowles, J. C., & Kim, H. (2020) · Journal of Tissue Engineering · doi:10.1177/2041731419897460 · Cited by 54

Nanobodies as modulators of inflammation: potential applications for acute brain injury

Rissiek, B., Koch‐Nolte, F., & Magnus, T. U. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00344 · Cited by 57

A novel gene editing system to treat both Tay–Sachs and sandhoff diseases

Ou, L., Przybilla, M. J., Tăbăran, A.-F., Overn, P., O’Sullivan, M. G., Jiang, X., Sidhu, R., Kell, P. J., Ory, D. S., & Whitley, C. B. (2020) · Gene Therapy · doi:10.1038/s41434-019-0120-5 · Cited by 52

Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma

Liu, Y., Zhang, D., An, Y., Sun, Y., Li, J., Zheng, M., Zou, Y., & Shi, B. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101790 · Cited by 52

Effective Intravenous Therapy for Neurodegenerative Disease With a Therapeutic Enzyme and a Peptide That Mediates Delivery to the Brain

Meng, Y., Sohár, I., Sleat, D. E., Richardson, J. R., Reuhl, K. R., Jenkins, R. B., Sarkar, G., & Lobel, P. (2013) · Molecular Therapy · doi:10.1038/mt.2013.267 · Cited by 51

Polyethylene glycol-b-poly(lactic acid) Polymersomes As Vehicles for Enzyme Replacement Therapy

Kelly, J. M., Gross, A. L., Martin, D. R., & Byrne, M. E. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0221 · Cited by 49

Dendrimers as Effective Carriers for the Treatment of Brain Tumor

Gorain, B., Choudhury, H., Pandey, M., Amin, M. C. I. M., Singh, B., Gupta, U. D., & Kesharwani, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812218-1.00010-5 · Cited by 49

Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins

Pavani, G., Laurent, M., Fabiano, A., Cantelli, E., Sakkal, A., Corre, G., Lenting, P. J., Concordet, J., Toueille, M., Miccio, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17552-3 · Cited by 54

Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice

Qin, H., Jiang, Y., Zhang, J., Deng, C., & Zhong, Z. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00691 · Cited by 49

Cancer research by means of tissue engineering – is there a rationale?

Horch, R. E., Boos, A. M., Quan, Y., Bleiziffer, O., Detsch, R., Boccaccini, A. R., Alexiou, C., Sun, J., Beier, J. P., & Arkudas, A. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12130 · Cited by 48

Delivering gene therapy for mucopolysaccharide diseases

Wood, S., & Bigger, B. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.965089 · Cited by 47

B3Pdb: an archive of blood–brain barrier-penetrating peptides

Kumar, V. D., Patiyal, S., Kumar, R., Sahai, S., Kaur, D., Lathwal, A., & Raghava, G. P. S. (2021) · Brain Structure and Function · doi:10.1007/s00429-021-02341-5 · Cited by 47

The interaction between particles and vascular endothelium in blood flow

Li, X., Zou, J., He, Z., Sun, Y., Song, X., & He, W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115216 · Cited by 43

Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches

Firdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042320 · Cited by 46

Peptide based drug delivery systems to the brain

Islam, Y., Leach, A. G., Smith, J. A., Pluchino, S., Coxon, C. R., Sivakumaran, M., Downing, J. R., Fatokun, A. A., Teixidò, M., & Ehtezazi, T. (2020) · Nano Express · doi:10.1088/2632-959x/ab9008 · Cited by 41

Identification and characterization of Nanobodies targeting the EphA4 receptor

Schoonaert, L., Rué, L., Roucourt, B., Timmers, M., Little, S., Chávez‐Gutiérrez, L., Dewilde, M., Joyce, P. I., Curnock, A. P., Weber, P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.774141 · Cited by 38

Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system

Scarpa, M., Bellettato, C. M., Lampe, C., & Begley, D. J. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.12.001 · Cited by 40

An overview of hypocretin based therapy in narcolepsy

Takenoshita, S., Sakai, N., Chiba, Y., Matsumura, M., Yamaguchi, M., & Nishino, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1459561 · Cited by 33

Nanobodies and Cancer: Current Status and New Perspectives

Allegra, A., Innao, V., Gerace, D. G., Vaddinelli, D., Allegra, A. G., & Musolino, C. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1458858 · Cited by 34

Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma

Li, Y., Wei, J., Wei, Y., Cheng, L., Guo, B., Meng, F., Li, F., & Zhong, Z. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01419 · Cited by 34

Recent Strategies for Targeted Brain Drug Delivery

Ogawa, K., Kato, N., & Kawakami, S. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00041 · Cited by 34

Development of an apolipoprotein E mimetic peptide–lipid conjugate for efficient brain delivery of liposomes

Kato, N., Yamada, S., Suzuki, R., Iida, Y., Matsumoto, M., Fumoto, S., Arima, H., Mukai, H., & Kawakami, S. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2173333 · Cited by 33

Phage display as a tool to discover blood–brain barrier ( BBB )‐shuttle peptides: panning against a human BBB cellular model

Díaz‐Perlas, C., Sánchez‐Navarro, M., Oller‐Salvia, B., Moreno, M. R., Teixidò, M., & Giralt, E. (2016) · Biopolymers · doi:10.1002/bip.22928 · Cited by 33

ApoE-modified liposomes encapsulating resveratrol and salidroside alleviate manifestations of Alzheimer’s disease in APP/PS-1 mice

Chen, M.-H., Liu, X., Qu, X., Guo, R., Zhang, L., Kong, L., Yu, Y., Liu, Y., Zang, J., Li, X., et al. (2023) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2023.2252062 · Cited by 33

Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain

Sarkar, G., Curran, G. L., Sarkaria, J. N., Lowe, V. J., & Jenkins, R. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097655 · Cited by 33

Emerging therapies for neuropathic lysosomal storage disorders

Kelly, J. M., Bradbury, A. M., Martin, D. R., & Byrne, M. E. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.002 · Cited by 32

Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood–Brain Barrier and Blood–Tumor Barrier

Pinkiewicz, M., Zaczyński, A., Walecki, J. M., & Zawadzki, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157050 · Cited by 36

An Engineered Galactosylceramidase Construct Improves AAV Gene Therapy for Krabbe Disease in Twitcher Mice

Pan, X., Sands, S. A., Yue, Y., Zhang, K., LeVine, S. M., & Duan, D. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.008 · Cited by 29

Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides

Dastpeyman, M., Sharifi, R., Amin, A., Karas, J. A., Cuic, B., Pan, Y., Nicolazzo, J. A., Turner, B. J., & Shabanpoor, F. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120398 · Cited by 28

Designing the future of nanomedicine: current barriers to targeted brain therapeutics

Herda, L. M., Polo, E., Kelly, P. M., Rocks, L., Hudecz, D., & Dawson, K. A. (2014) · European Journal of Nanomedicine · doi:10.1515/ejnm-2014-0022 · Cited by 30

Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects

Li, Y., Zhang, Y., Hu, Q., Egranov, S. D., Xing, Z., Zhang, Z., Liang, K., Ye, Y., Pan, Y., Chatterjee, S. S., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00937-4 · Cited by 27

Small, Smart, and LDLR-Specific Micelles Augment Sorafenib Therapy of Glioblastoma

Wei, J., Xia, Y., Meng, F., Ni, D., Qiu, X., & Zhong, Z. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c01103 · Cited by 27

Brain metastasis models: What should we aim to achieve better treatments?

Masmudi‐Martín, M., Zhu, L., Sánchez‐Navarro, M., Priego, N., Casanova-Acebes, M., Ruiz‐Rodado, V., Giralt, E., & Valiente, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.002 · Cited by 27

Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis

Che, L., Yang, X., Ge, C., El‐Amouri, S. S., Wang, Q.-E., Pan, D., Herzog, T. J., & Du, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216553 · Cited by 23

Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs

Teng, F., Liu, J., Cui, T., Tan, X., Liu, K., Hou, Z., (54356), L. Z., Xie, Y., Li, R., Li, D., et al. (2026) · Cell · doi:10.1016/j.cell.2026.01.034 · Cited by 25

Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier

Critchley, B. J., Gaspar, H. B., & Benedetti, S. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.015 · Cited by 25

RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system

Ou, L., Przybilla, M. J., Koniar, B. L., & Whitley, C. B. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.11.013 · Cited by 23

Programmable DNA Nanodevices for Applications in Neuroscience

Hivare, P., Panda, C., Gupta, S. K., & Bhatia, D. D. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00723 · Cited by 21

Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes

Guo, S., & Yi, C. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2023-0158 · Cited by 25

Application prospect of peptide-modified nano targeting drug delivery system combined with PD-1/PD-L1 based immune checkpoint blockade in glioblastoma

Song, P., Zhao, X., & Xiao, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119865 · Cited by 22

Normalization and Improvement of CNS Deficits in Mice With Hurler Syndrome After Long-term Peripheral Delivery of BBB-targeted Iduronidase

El‐Amouri, S. S., Dai, M., Han, J., Brady, R. O., & Pan, D. (2014) · Molecular Therapy · doi:10.1038/mt.2014.152 · Cited by 22

Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease

Dai, M., Liou, B., Swope, B., Wang, X., Zhang, W., Inskeep, V., Grabowski, G. A., Sun, Y., & Pan, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162367 · Cited by 21

Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos

David, M., Lécorché, P., Masse, M., Faucon, A., Abouzid, K., Gaudin, N., Varini, K., Gassiot, F., Ferracci, G., Jacquot, G., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191052 · Cited by 23

Anchoring Microbubbles on Cerebrovascular Endothelium as a New Strategy Enabling Low‐Energy Ultrasound‐Assisted Delivery of Varisized Agents Across Blood‐Brain Barrier

Li, B., Lin, Y., Chen, G., Cai, M., Zhong, H., Xiao, Z., Lin, M., Li, T., Cai, Y., Shuai, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202302134 · Cited by 21

Designing and Characterization of a Novel Delivery System for Improved Cellular Uptake by Brain Using Dendronised Apo-E-Derived Peptide

Al-azzawi, S., Masheta, D., Guildford, A. L., Phillips, G. J., & Santin, M. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00049 · Cited by 20

Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy

Miwa, S., Watabe, A. M., Shimada, Y., Higuchi, T., Kobayashi, H., Fukuda, T., Kato, F., Ida, H., & Ohashi, T. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.06.007 · Cited by 20

Hematopoietic Stem cell transplantation and lentiviral vector‐based gene therapy for Krabbe's disease: Present convictions and future prospects

Hu, P., Li, Y., Nikolaishvili‐Feinberg, N., Scesa, G., Bi, Y., Pan, D., Moore, D. T., Bongarzone, E. R., Sands, M. S., Miller, C. R., et al. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23847 · Cited by 19

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?

Horgan, C., Jones, S. A., Bigger, B., & Wynn, R. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094854 · Cited by 18

Models to study basic and applied aspects of lysosomal storage disorders

Gaudioso, Á., Silva, T. P., & Ledesma, M. D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114532 · Cited by 18

Single enzyme nanoparticle, an effective tool for enzyme replacement therapy

Kim, D. H., Lee, H. S., Kwon, T.-W., Han, Y.-M., Kang, N.-W., Lee, M. Y., Kim, D., Kim, M. G., & Lee, J. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01216-3 · Cited by 17

Hurdles in treating Hurler disease: potential routes to achieve a “real” cure

van den Broek, B. T. A., van Doorn, J., Hegeman, C. V., Nierkens, S., Lindemans, C. A., Verhoeven‐Duif, N. M., Boelens, J. J., & van Hasselt, P. M. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001708 · Cited by 17

Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease

Dogan, Y., Barese, C. N., Schindler, J. W., Yoon, J. K., Unnisa, Z., Guda, S., Jacobs, M. E., Oborski, C., Maiwald, T., Clarke, D. L., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.017 · Cited by 17

Brain-targeted multifunctional micelles delivering Oridonin and Phillyrin for synergistic therapy of Alzheimer's disease

Yu, Y., He, S.-Y., Kong, L., Shi, N.-N., Liu, Y., Zang, J., Guo, R., Zhang, L., Li, X., & Li, X. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104794 · Cited by 16

Understanding the In Vivo Fate of Advanced Materials by Imaging

Li, R., Ng, T. S. C., Garlin, M. A., Weissleder, R., & Miller, M. A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910369 · Cited by 18

Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler Syndrome

Dai, M., Han, J., El‐Amouri, S. S., Brady, R. O., & Pan, D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323155111 · Cited by 16

miR-143 Regulates Lysosomal Enzyme Transport across the Blood-Brain Barrier and Transforms CNS Treatment for Mucopolysaccharidosis Type I

Lin, Y., Wang, X., Rose, K. P., Dai, M., Han, J., Xin, M., & Pan, D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.011 · Cited by 15

Mucopolysaccharidoses and the blood–brain barrier

Sahin, O., Thompson, H. P., Goodman, G. W., Li, J., & Urayama, A. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00373-5 · Cited by 16

Characterization Of Blood–Brain Barrier Crossing And Tumor Homing Peptides By Molecular Dynamics Simulations

Arcangeli, C., Lico, C., Baschieri, S., & Mancuso, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s225793 · Cited by 14

Brain delivery and activity of a lysosomal enzyme using a blood–brain barrier transport vehicle in mice

Ullman, J. C., Arguello, A., Getz, J. A., Bhalla, A., Mahon, C. S., Wang, J., Giese, T., Bedard, C., Kim, D. J., Blumenfeld, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1163 · Cited by 205

Improved brain uptake and efficacy of iduronate 2-sulfatase with the enzyme transport vehicle

Henry, A. G., Kariolis, M. S., Ullman, J. C., Getz, J. A., Arguello, A., Mahon, C. S., Wang, J., Bhalla, A., Giese, T., Bédard, C., et al. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.12.174 · Cited by 1

Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrier

Boado, R. J., Zhang, Y., Zhang, Y., Xia, C., Wang, Y., & Pardridge, W. M. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21602 · Cited by 142

Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A

Böckenhoff, A., Cramer, S., Wölte, P., Knieling, S., Wohlenberg, C., Gieselmann, V., Galla, H., & Matzner, U. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4785-13.2014 · Cited by 103

Non-clinical evaluation of a blood-brain barrier-penetrating enzyme for the treatment of mucopolysaccharidosis type I

Kida, S., Kinoshita, M., Tanaka, S., Okumura, M., Koshimura, Y., & Morimoto, H. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.12.205 · Cited by 5